
Gilead Sciences (GILD) Stock Forecast & Price Target
Gilead Sciences (GILD) Analyst Ratings
Bulls say
Gilead Sciences is a leading biopharmaceutical company with a strong focus on developing and marketing therapies for life-threatening infectious diseases. The recent acquisition of Arcellx, adding potential blockbuster CAR-T cell therapy anito-cel to Gilead's already strong portfolio of HIV and hepatitis drugs, provides a significant boost to the company's future potential revenue streams. Furthermore, Gilead's consistent financial performance, with solid revenue and income growth, combined with strategic investments and partnerships, make it a strong candidate for long-term growth and success in the healthcare sector.
Bears say
Gilead Sciences is facing potential risks to their revenue forecast, including increased competition from other companies in the biopharmaceutical industry, potential legal and regulatory challenges, and potential manufacturing and commercial challenges. Additionally, their forecasted sales for Yescarta are below market expectations, but this is offset by expected growth in the entire PrEP market. Despite a strong performance in their HIV franchise, Gilead's overall revenue growth is expected to be negatively impacted by policy changes and declining sales of Veklury. To counter this, Gilead has made strategic acquisitions in the oncology market, but concerns remain over the success of these acquisitions and the potential for further impairment charges. Looking forward, approvals and launches of potential key products such as Trodelvy and anito-cel in the next few years may provide upside, but competition in the CAR-T market could limit potential growth.
This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.
Gilead Sciences (GILD) Analyst Forecast & Price Prediction
Start investing in Gilead Sciences (GILD)
Order type
Buy in
Order amount
Est. shares
0 shares